COVID-19 vaccines may not produce sufficient antibody response in transplant recipients

When clinical trials were conducted to determine the immunogenicity -- the ability to elicit an immune response -- for the first two vaccines marshaled against SARS-CoV-2the virus that causes COVID-19, one group was not among those included: people who have received solid organ transplants and others (such as those with autoimmune disorders) who are immunocompromised.